

Grzegorz S Nowakowski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5724707/publications.pdf>

Version: 2024-02-01

249
papers

5,031
citations

117453

34
h-index

110170

64
g-index

250
all docs

250
docs citations

250
times ranked

6719
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. <i>JAMA Oncology</i> , 2019, 5, 1008.	3.4	526
2	Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non-Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 251-257.	0.8	319
3	AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1188-1199.	0.8	277
4	Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. <i>Journal of Clinical Oncology</i> , 2013, 31, 3272-3278.	0.8	259
5	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 1096-1101.	2.0	180
6	ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1317-1328.	0.8	132
7	Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 1658-1671.	1.9	122
8	A Phase I Trial of Twice-Weekly 17-Allylamino-Demethoxy-Geldanamycin in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 6087-6093.	3.2	112
9	Diagnosis and Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2017, 3, 1257.	3.4	110
10	Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. <i>Haematologica</i> , 2020, 105, 348-357.	1.7	105
11	ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e449-e457.	1.8	102
12	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. <i>American Journal of Human Genetics</i> , 2014, 95, 462-471.	2.6	96
13	Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 1603-1610.	0.8	93
14	The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. <i>Blood</i> , 2015, 126, 328-335.	0.6	92
15	Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2018, 93, 57-68.	1.3	90
16	Pattern of CD14+ Follicular Dendritic Cells and PD1+ T Cells Independently Predicts Time to Transformation in Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 2862-2872.	3.2	86
17	ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2016, 12, 1553-1563.	1.1	85
18	The diagnosis and treatment of primary vitreoretinal lymphoma: a review. <i>International Journal of Retina and Vitreous</i> , 2018, 4, 18.	0.9	85

#	ARTICLE	IF	CITATIONS
19	The efficacy of ibrutinib in the treatment of Richter syndrome. <i>Blood</i> , 2015, 125, 1676-1678.	0.6	83
20	Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era. <i>Journal of Clinical Oncology</i> , 2010, 28, 412-417.	0.8	75
21	Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials. <i>JAMA Network Open</i> , 2020, 3, e2012534.	2.8	72
22	Percentage of Smudge Cells on Routine Blood Smear Predicts Survival in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 1844-1849.	0.8	71
23	Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement. <i>Journal of Clinical Oncology</i> , 2022, 40, 2163-2171.	0.8	68
24	American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care. <i>Journal of Clinical Oncology</i> , 2021, 39, 155-169.	0.8	65
25	Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. <i>Journal of Clinical Oncology</i> , 2021, 39, 1329-1338.	0.8	60
26	Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. <i>International Journal of Epidemiology</i> , 2017, 46, 1753-1754i.	0.9	57
27	Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw257.	3.0	56
28	Using Smudge Cells on Routine Blood Smears to Predict Clinical Outcome in Chronic Lymphocytic Leukemia: A Universally Available Prognostic Test. <i>Mayo Clinic Proceedings</i> , 2007, 82, 449-453.	1.4	55
29	Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. <i>Oncotarget</i> , 2017, 8, 27145-27154.	0.8	55
30	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). <i>Oncologist</i> , 2015, 20, 1149-1153.	1.9	52
31	Inferior survival in high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements is not associated with <i>MYC/IG</i> gene rearrangements. <i>Haematologica</i> , 2018, 103, 1899-1907.	1.7	52
32	Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. <i>British Journal of Haematology</i> , 2017, 179, 50-60.	1.2	49
33	Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 1819-1827.	0.8	44
34	Diffuse large B-cell lymphoma: new targets and novel therapies. <i>Blood Cancer Journal</i> , 2021, 11, 68.	2.8	41
35	Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018. <i>American Journal of Hematology</i> , 2019, 94, 291-298.	2.0	40
36	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 73.	2.8	37

#	ARTICLE	IF	CITATIONS
37	Impact of MYD88 ^{L265P} mutation status on histological transformation of Waldenström Macroglobulinemia. American Journal of Hematology, 2020, 95, 274-281.	2.0	33
38	The Presence of Intratumoral CD14 Positive Cells Is Associated with Transformation of Follicular Lymphoma to Diffuse Large B Cell Lymphoma.. Blood, 2012, 120, 2700-2700.	0.6	31
39	A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. Blood, 2019, 134, 467-467.	0.6	29
40	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. Leukemia, 2019, 33, 790-794.	3.3	28
41	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. Leukemia, 2021, 35, 522-533.	3.3	28
42	Lack of intrafollicular memory CD4 ⁺ T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. Blood Cancer Journal, 2021, 11, 130.	2.8	27
43	Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. American Journal of Hematology, 2017, 92, 448-453.	2.0	26
44	History of autoimmune conditions and lymphoma prognosis. Blood Cancer Journal, 2018, 8, 73.	2.8	26
45	Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. Blood, 2019, 134, 1289-1297.	0.6	26
46	Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. Blood Cancer Journal, 2019, 9, 48.	2.8	24
47	RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2021, 27, 6124-6134.	3.2	24
48	Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies. Blood, 2019, 134, 5345-5345.	0.6	24
49	CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies. Blood Cancer Journal, 2018, 8, 63.	2.8	22
50	Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2020, 71, 1221-1228.	2.9	22
51	Human leucocyte antigen class I and killer immunoglobulin-like receptor expression patterns in T-cell large granular lymphocyte leukaemia. British Journal of Haematology, 2005, 128, 490-492.	1.2	20
52	Human Pegivirus infection and lymphoma risk and prognosis: a North American study. British Journal of Haematology, 2018, 182, 644-653.	1.2	20
53	Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma. Journal of Hematology and Oncology, 2018, 11, 57.	6.9	19
54	A roadmap for discovery and translation in lymphoma. Blood, 2015, 125, 2175-2177.	0.6	18

#	ARTICLE	IF	CITATIONS
55	Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. <i>Blood Cancer Journal</i> , 2020, 10, 117.	2.8	18
56	Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era. <i>Blood Advances</i> , 2021, 5, 1379-1387.	2.5	18
57	Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment. <i>Current Treatment Options in Oncology</i> , 2022, 23, 155-170.	1.3	17
58	Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?. <i>Journal of Clinical Oncology</i> , 2021, 39, 1641-1649.	0.8	16
59	First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy. <i>Clinical Cancer Research</i> , 2022, 28, 1285-1293.	3.2	16
60	Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma. <i>British Journal of Haematology</i> , 2017, 178, 427-433.	1.2	15
61	Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 786-793.	2.0	15
62	Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial. <i>International Journal of Hematology</i> , 2022, 115, 222-232.	0.7	15
63	Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. <i>Clinical Cancer Research</i> , 2022, 28, 4003-4017.	3.2	15
64	Analysis and impact of a multidisciplinary lymphoma virtual tumor board. <i>Leukemia and Lymphoma</i> , 2020, 61, 3351-3359.	0.6	14
65	Proteomic Analysis of Chronic Lymphocytic Leukemia Cells Identifies Vimentin as a Novel Prognostic Factor for Aggressive Disease.. <i>Blood</i> , 2005, 106, 707-707.	0.6	14
66	Retinoic acid receptor alpha drives cell cycle progression and is associated with increased sensitivity to retinoids in T-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 26245-26255.	0.8	14
67	Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 186, 820-828.	1.2	12
68	ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1. <i>Future Oncology</i> , 2020, 16, 991-999.	1.1	12
69	Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2021, 96, 945-953.	2.0	12
70	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2021, 195, 210-216.	1.2	12
71	Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 699-704.	0.2	11
72	Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2020, 105, e72-e75.	1.7	11

#	ARTICLE	IF	CITATIONS
73	RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2020, 38, 8020-8020.	0.8	11
74	Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era. Blood Cancer Journal, 2018, 8, 27.	2.8	10
75	Identification of Factors Associated with Hematology-Oncology Fellow Academic Success and Career Choice. Journal of Cancer Education, 2019, 34, 1219-1224.	0.6	10
76	A Graduate-Level Interdisciplinary Curriculum in CAR-T Cell Therapy. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2020, 4, 203-210.	1.2	10
77	A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses. Leukemia and Lymphoma, 2019, 60, 559-561.	0.6	9
78	T cell/histiocyte-rich large B cell lymphoma: incidence, demographic disparities, and long-term outcomes. British Journal of Haematology, 2019, 185, 140-142.	1.2	9
79	Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?. Leukemia and Lymphoma, 2020, 61, 318-327.	0.6	9
80	Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma. Blood Cancer Journal, 2021, 11, 8.	2.8	9
81	AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. Blood, 2018, 132, 445-445.	0.6	9
82	Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro. Blood, 2019, 134, 2859-2859.	0.6	9
83	Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. Blood Advances, 2022, 6, 1350-1360.	2.5	9
84	Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab. American Journal of Hematology, 2017, 92, 1156-1162.	2.0	8
85	End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma. PET Clinics, 2019, 14, 307-315.	1.5	8
86	Relapsed/Refractory International Prognostic Index (R-R&PI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma. American Journal of Hematology, 2021, 96, 599-605.	2.0	8
87	First-MIND: A phase Ib, open-label, randomized study to assess safety of tafasitamab (tafa) or tafa + lenalidomide (LEN) in addition to R-CHOP in patients with newly diagnosed DLBCL.. Journal of Clinical Oncology, 2021, 39, 7540-7540.	0.8	8
88	Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type. Hematological Oncology, 2021, 39, 658-663.	0.8	8
89	Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma. Blood, 2018, 132, 4168-4168.	0.6	8
90	Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study. Blood, 2020, 136, 44-45.	0.6	8

#	ARTICLE	IF	CITATIONS
91	Combination of Lenalidomide with R-CHOP (R2CHOP) Is Well-Tolerated and Effective As Initial Therapy for Aggressive B-Cell Lymphomas - A Phase II Study. <i>Blood</i> , 2012, 120, 689-689.	0.6	8
92	Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 183-183.	0.6	8
93	Waldenström Macroglobulinemia in the Very Elderly (≥75 years): Clinical Characteristics and Outcomes. <i>Blood</i> , 2020, 136, 44-45.	0.6	8
94	Targetability of STAT3-JAK2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tract. <i>Leukemia</i> , 2020, 34, 1467-1471.	3.3	7
95	Treatment of Aggressive B Cell Lymphomas: Updates in 2019. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 225-234.	1.2	7
96	Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma. <i>Blood</i> , 2019, 134, 121-121.	0.6	7
97	Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials. <i>Blood Cancer Journal</i> , 2022, 12, 1.	2.8	7
98	A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 664-672.e2.	0.2	6
99	Treatment Patterns and Outcomes of DLBCL after Failure of Front-Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 2683-2683.	0.6	6
100	Immune Epigenetic Crosstalk Between Malignant B Cells and the Tumor Microenvironment in B Cell Lymphoma. <i>Frontiers in Genetics</i> , 2022, 13, 826594.	1.1	6
101	Evolution: IMiDs to PPMs, revolution in DLBCL?. <i>Blood</i> , 2015, 126, 698-700.	0.6	5
102	Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. <i>British Journal of Haematology</i> , 2018, 183, 149-152.	1.2	5
103	<p>Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy</p>. <i>Clinical Epidemiology</i> , 2019, Volume 11, 987-996.	1.5	5
104	Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era. <i>American Journal of Hematology</i> , 2021, 96, 979-988.	2.0	5
105	Initial Presentation and Prognostic Factors in 286 Patients with T-Cell Large Granular Lymphocyte Leukemia.. <i>Blood</i> , 2006, 108, 300-300.	0.6	5
106	A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas. <i>Blood</i> , 2010, 116, 287-287.	0.6	5
107	Primary Pulmonary MALT Lymphoma: Clinical Characteristics and Treatment Outcomes â€“ Single Institution Experience. <i>Blood</i> , 2010, 116, 4168-4168.	0.6	5
108	Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials. <i>Blood</i> , 2016, 128, 3034-3034.	0.6	5

#	ARTICLE	IF	CITATIONS
109	Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 3035-3035.	0.6	5
110	Recent advances in clinical studies and the evolving role of subtyping for patients with diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2017, 13, 859-862.	1.1	4
111	Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker?. <i>Nutrition and Cancer</i> , 2018, 70, 1088-1090.	0.9	4
112	Aspirin and other nonsteroidal anti-inflammatory drugs, statins and risk of non-Hodgkin lymphoma. <i>International Journal of Cancer</i> , 2021, 149, 535-545.	2.3	4
113	Outcomes in mantle cell lymphoma with central nervous system involvement.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19527-e19527.	0.8	4
114	Safety and efficacy of VIP152, a CDK9 inhibitor, in patients with double-hit lymphoma (DHL).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7538-7538.	0.8	4
115	Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. <i>Blood Cancer Journal</i> , 2021, 11, 133.	2.8	4
116	Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies. <i>Blood</i> , 2019, 134, 4092-4092.	0.6	4
117	Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information. <i>Blood</i> , 2019, 134, 5327-5327.	0.6	4
118	<sc>RNAseq</sc> identification of <sc>FISH</sc> â€cryptic <i><sc>BCL6</sc> :: <sc>TP63</sc></i> rearrangement in <sc>ALK</sc> â€negative anaplastic large cell lymphoma. <i>Histopathology</i> , 2022, , .	1.6	4
119	Testicular <sc>FDGâ€PET</sc>/<sc>CT</sc> uptake threshold in aggressive lymphomas. <i>American Journal of Hematology</i> , 2021, 96, E81-E83.	2.0	3
120	Progression-free survival at 24 months as a landmark after autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7522-7522.	0.8	3
121	A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies. <i>Leukemia and Lymphoma</i> , 2021, 62, 2625-2636.	0.6	3
122	Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. <i>Blood Cancer Journal</i> , 2021, 11, 160.	2.8	3
123	A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial. <i>Blood</i> , 2019, 134, 2877-2877.	0.6	3
124	Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 1604-1604.	0.6	3
125	A Prospective Multicenter Study of Minimal Residual Disease Assessment Using a Next-Generation Immunosequencing Assay and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 52-52.	0.6	3
126	Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy. <i>Blood</i> , 2021, 138, 2527-2527.	0.6	3

#	ARTICLE	IF	CITATIONS
127	Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies.. Journal of Clinical Oncology, 2022, 40, 7575-7575.	0.8	3
128	Predictors of short-term survival in Waldenström Macroglobulinemia. Leukemia and Lymphoma, 2020, 61, 2975-2979.	0.6	2
129	A practical approach to FISH testing for MYC rearrangements and brief review of MYC in aggressive B-cell lymphomas. Journal of Hematopathology, 2020, 13, 127-135.	0.2	2
130	Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Trials in Progress).. Journal of Clinical Oncology, 2021, 39, TPS7571-TPS7571.	0.8	2
131	Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.. Journal of Clinical Oncology, 2021, 39, e19547-e19547.	0.8	2
132	An Analysis of a Multidisciplinary Lymphoma Virtual Tumor Board with Regional and International Participation. Blood, 2018, 132, 2247-2247.	0.6	2
133	Subgroup Analyses of Elderly Patients Aged ≥70 Years in ALIUMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). Blood, 2019, 134, 347-347.	0.6	2
134	Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC). Blood, 2019, 134, 400-400.	0.6	2
135	A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Analysis of the Safety Run-in Phase. Blood, 2020, 136, 27-28.	0.6	2
136	Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis. Blood, 2020, 136, 7-8.	0.6	2
137	Somatic Hyperrepair: A Novel Tumor Suppression Mechanism for Germinal Center B Cells.. Blood, 2009, 114, 92-92.	0.6	2
138	Phase 1 Trial of Sorafenib and Everolimus In Patients with Lymphoma or Multiple Myeloma.. Blood, 2010, 116, 2802-2802.	0.6	2
139	Genetic Polymorphisms In Genes Involved In R-CHOP Metabolism and Event-Free and Overall Survival In Diffuse Large B-Cell Lymphoma. Blood, 2010, 116, 996-996.	0.6	2
140	An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 1874-1874.	0.6	2
141	Lenalidomide Plus R-CHOP (R2CHOP) in Patients with DLBCL Is Associated with a Lower Risk of CNS Relapse: Combined Analysis from Two Phase 2 Studies. Blood, 2016, 128, 3033-3033.	0.6	2
142	Cytogenetic Analysis of Normal Human B Cells Following CpG Stimulation: Implications for Interpretation of CpG Induced CLL Metaphase Analysis. Blood, 2008, 112, 3124-3124.	0.6	2
143	Potential Pathogenetic Role of Achromobacter (Alcaligenes) Xylosoxidans in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSG. Blood, 2011, 118, 880-880.	0.6	2
144	Central Nervous System Involvement in Peripheral T-Cell Lymphoma. Blood, 2019, 134, 5293-5293.	0.6	2

#	ARTICLE	IF	CITATIONS
145	A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR) T J ETQq1 1 0.784314 rgB1/Overlook	1.1	1
146	Impact of Novel Agents on the Outcomes of Patients with Classic Hodgkin Lymphoma That Relapsed after Autologous Stem Cell Transplant. <i>Blood</i> , 2021, 138, 1373-1373.	0.6	2
147	The Impact of Prior Treatment with a CD19 Targeting Monoclonal Antibody on Subsequent Treatment with CD19 Targeting CART Cell Therapy in Preclinical Models. <i>Blood</i> , 2021, 138, 2412-2412.	0.6	2
148	First-Mind: Primary Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 3556-3556.	0.6	2
149	Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e815-e825.	0.2	2
150	Availability of data for screening, offering, and consenting patients to cancer clinical trials: Report from an ASCO-ACCC collaboration.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6530-6530.	0.8	2
151	Reply to R.S. Go. <i>Journal of Clinical Oncology</i> , 2009, 27, e45-e45.	0.8	1
152	Holistic review for hematology&oncology fellowship applicants: A new paradigm?. <i>American Journal of Hematology</i> , 2020, 95, 1124-1126.	2.0	1
153	Survival trends of older adult patients with diffuse large B-cell lymphoma: A National Cancer Database analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7542-7542.	0.8	1
154	Type of tissue biopsy and outcomes in diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2021, 39, e13569-e13569.	0.8	1
155	Salvage therapies in transplant-eligible relapsed classic Hodgkin lymphoma, are novel regimens better?. <i>Journal of Clinical Oncology</i> , 2021, 39, 7530-7530.	0.8	1
156	Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era. <i>Blood</i> , 2018, 132, 454-454.	0.6	1
157	Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL. <i>Blood</i> , 2018, 132, 4204-4204.	0.6	1
158	High Efficacy of Lenalidomide Plus R-CHOP (R2CHOP) Combination in First Line Treatment of Activated B-Cell (ABC) DLBCL Defined Using Gene-Expression Profiling: A Combined Analysis from Two Phase 2 Trials. <i>Blood</i> , 2018, 132, 2962-2962.	0.6	1
159	Engine: Phase III Randomized Study of Enzastaurin/R-CHOP Versus Placebo/R-CHOP in Frontline High Risk Diffuse Large B Cell Lymphoma Patients with Novel Genomic Biomarker DGM1. <i>Blood</i> , 2019, 134, 5330-5330.	0.6	1
160	Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study. <i>Blood</i> , 2019, 134, 4090-4090.	0.6	1
161	Clinical Features and Treatment for Neurolymphomatosis in the Rituximab Era: Single Institution Experience. <i>Blood</i> , 2019, 134, 4129-4129.	0.6	1
162	Interphase Fluorescence In Situ Hybridization (FISH) with an IgH Probe Is Important in the Management of Patients with a Clinical Diagnosis of Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2004, 104, 1919-1919.	0.6	1

#	ARTICLE	IF	CITATIONS
163	Smudge Cells on Routine Blood Smear Predict Clinical Outcome in Chronic Lymphocytic Leukemia: A Universally Available Prognostic Test.. Blood, 2006, 108, 2785-2785.	0.6	1
164	Primary Parotid MALT Lymphoma: Clinical Characteristics and Treatment â€“ a Single Institution Experience. Blood, 2011, 118, 1580-1580.	0.6	1
165	Prior Rituximab Exposure Does Not Appear to Affect Time to Treatment Failure After Radioimmunotherapy. Blood, 2011, 118, 1640-1640.	0.6	1
166	Resistance to Complement Dependent Cytotoxicity in CLL Cells From Patients Treated with Ofatumumab. Blood, 2011, 118, 2836-2836.	0.6	1
167	Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era. Blood, 2015, 126, 3992-3992.	0.6	1
168	Everolimus Plus RCHOP-21 Is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG1085 (Alliance). Blood, 2015, 126, 813-813.	0.6	1
169	Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma. Blood, 2016, 128, 1104-1104.	0.6	1
170	Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas). Blood, 2016, 128, 155-155.	0.6	1
171	Randomized, phase III trial of the efficacy and safety of lenalidomide plus R-CHOP vs R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma.. Journal of Clinical Oncology, 2015, 33, TPS8600-TPS8600.	0.8	1
172	Crosstalk between Chronic Lymphocytic Leukemia (CLL) B-Cells and Marrow Stromal Cells: Implication for CLL B-Cell Activation and Survival.. Blood, 2007, 110, 337-337.	0.6	1
173	The Absolute Monocyte Count Predicts Overall Survival In Patients Newly Diagnosed with Follicular Lymphoma. Blood, 2011, 118, 85-85.	0.6	1
174	Clinical Significance of Testicular FDG-PET/CT Uptake in Aggressive Lymphomas. Blood, 2018, 132, 5401-5401.	0.6	1
175	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. Blood, 2018, 132, 2884-2884.	0.6	1
176	Mayo Clinic Hematology Fellowship for Advanced Practice Providers. Journal of the Advanced Practitioner in Oncology, 2020, 11, 395-400.	0.2	1
177	Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study. Blood, 2021, 138, 1415-1415.	0.6	1
178	Vaccination History and Risk of Lymphoma and Its Major Subtypes. Cancer Epidemiology Biomarkers and Prevention, 2021, , cebp.0383.2021.	1.1	1
179	Central Nervous System Involvement By Mantle Cell Lymphoma. Blood, 2021, 138, 2426-2426.	0.6	1
180	Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ECHELON-3, Trial in Progress). Blood, 2021, 138, 3564-3564.	0.6	1

#	ARTICLE	IF	CITATIONS
181	Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era. <i>Blood</i> , 2021, 138, 2429-2429.	0.6	1
182	Time to Refractory Status Defines Subsets of Primary Refractory Diffuse Large B-Cell Lymphoma with Distinct Outcomes. <i>Blood</i> , 2021, 138, 2524-2524.	0.6	1
183	Central Nervous System (CNS) Involvement of Richter Transformation: A Single Center Experience. <i>Blood</i> , 2020, 136, 3-4.	0.6	1
184	A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies. <i>Blood</i> , 2020, 136, 49-50.	0.6	1
185	Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 26-27.	0.6	1
186	Recently approved drugs herald a new era in therapy for diffuse large B-cell lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19, 284-287.	0.3	1
187	PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts. <i>Blood Cancer Journal</i> , 2022, 12, 78.	2.8	1
188	Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Safety and efficacy results from the safety run-in period of the phase 3 ECHELON-3 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7559-7559.	0.8	1
189	frontMIND: A phase III, randomized, double-blind study of tafasitamab + lenalidomide + R-CHOP versus R-CHOP alone for newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS7590-TPS7590.	0.8	1
190	Impact of time to relapse and response to salvage therapy on post autologous stem cell transplant outcomes in relapsed or refractory diffuse large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19501-e19501.	0.8	0
191	Diffuse large B-cell lymphoma with leukemic involvement.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19552-e19552.	0.8	0
192	Acquired Pure Red Cell Aplasia Associated with Clonal T-Cell Receptor (TCR) Gene Rearrangements with and without Pathologic Features of T-Cell Large Granular Lymphocytic Leukemia (T-LGLL).. <i>Blood</i> , 2004, 104, 2819-2819.	0.6	0
193	Prognostic Factors and Survival of Patients with Primary Mediastinal Large B-Cell Lymphoma.. <i>Blood</i> , 2005, 106, 4698-4698.	0.6	0
194	Targeting V α -4 Reduces Cell Adhesion Mediated Drug Resistance in Chronic Lymphocytic Leukemia: Rationale for Anti V α -4 Therapy.. <i>Blood</i> , 2005, 106, 1182-1182.	0.6	0
195	Neuropilin-1 Receptor (NRP-1) Occupancy Induces Cell Death in Primary Chronic Lymphocytic Leukemia (CLL) B Cells.. <i>Blood</i> , 2006, 108, 586-586.	0.6	0
196	Increased Cytotoxic T-Cell Infiltrates in the Bone Marrow Is an Independent Adverse Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.. <i>Blood</i> , 2007, 110, 1492-1492.	0.6	0
197	The Absolute Monocyte and Lymphocyte Counts at Diagnosis Predict Survival and Identify High-Risk Patients In Diffuse Large-B-Cell Lymphoma. <i>Blood</i> , 2010, 116, 3088-3088.	0.6	0
198	Elevation of Serum Free Light Chains Are Common In Lymphoma and Associated with Poor Event Free and Overall Survival. <i>Blood</i> , 2010, 116, 4136-4136.	0.6	0

#	ARTICLE	IF	CITATIONS
199	Interactions with the Microenvironment Protect Lymphoma B-Cells From Rituximab Induced Apoptosis and Could Represent a Therapeutic Target. <i>Blood</i> , 2010, 116, 3115-3115.	0.6	0
200	Phase II Clinical Trial of Denileukin Diftitox In Combination with Rituximab In Previously Untreated Follicular B-Cell Non-Hodgkin's Lymphoma. <i>Blood</i> , 2010, 116, 2862-2862.	0.6	0
201	Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Cell of Origin in Predicting Survival in Diffuse Large B-Cell Lymphoma,. <i>Blood</i> , 2011, 118, 3652-3652.	0.6	0
202	Utility of Stem Cell Collection in Anticipation of Future Need for Autologous Stem Cell Transplant in Follicular Lymphoma Patients. <i>Blood</i> , 2011, 118, 1926-1926.	0.6	0
203	Risk of Transformation of Follicular Lymphoma to High Grade Lymphoma After Radioimmunotherapy: A Prospective Observational Single Institutional Experience. <i>Blood</i> , 2011, 118, 1572-1572.	0.6	0
204	Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis and Survival in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,. <i>Blood</i> , 2011, 118, 3642-3642.	0.6	0
205	Phase I Trial of a Novel Combination of An HDAC Inhibitor (LBH589) and An mTOR Inhibitor (RAD001) in Lymphoid and Plasma Cell Malignancies. <i>Blood</i> , 2011, 118, 2682-2682.	0.6	0
206	Diffuse Large B-Cell Transformation in Nodular Lymphocyte Predominant Hodgkin Lymphoma: Incidence, Risk Factors and Outcomes After a Forty-Year Experience From a Single Institution. <i>Blood</i> , 2012, 120, 1525-1525.	0.6	0
207	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Interim Positron-Emission Tomography in Predicting Progression-Free Survival and Time to Progression in Classical Hodgkin Lymphoma (HL). <i>Blood</i> , 2012, 120, 1527-1527.	0.6	0
208	Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). <i>Blood</i> , 2012, 120, 684-684.	0.6	0
209	LR-CD: Efficacy of Combination Therapy with Lenalidomide for Untreated Indolent B-Cell NHL.. <i>Blood</i> , 2012, 120, 2741-2741.	0.6	0
210	Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era. <i>Blood</i> , 2012, 120, 149-149.	0.6	0
211	Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI. <i>Blood</i> , 2012, 120, 1563-1563.	0.6	0
212	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During ABVD Treatment Cycles Predicts Clinical Outcomes in Classical Hodgkin Lymphoma (HL).. <i>Blood</i> , 2012, 120, 2634-2634.	0.6	0
213	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During RCHOP Treatment Cycles Predicts Clinical Outcomes In Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2013, 122, 4306-4306.	0.6	0
214	Prognostic Correlates and Outcomes of Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma: An Analysis of 41 Consecutive Patients. <i>Blood</i> , 2015, 126, 3730-3730.	0.6	0
215	Study of the Subclonal Mutations in Primary Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 131-131.	0.6	0
216	Lymphocyte-to-Monocyte Ratio at Diagnosis and Survival in De Novo Double/Triple Hit Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 3885-3885.	0.6	0

#	ARTICLE	IF	CITATIONS
217	Survival Trends in Adult T-Acute Lymphoblastic Leukemia / Lymphoma (ALL), a Comparative Analysis of 92 Patients By Year of Diagnosis. <i>Blood</i> , 2015, 126, 2490-2490.	0.6	0
218	The Adverse Impact of Age and Central Nervous System Involvement on Survival in Adult T-ALL, an Analysis of 92 Consecutive Patients. <i>Blood</i> , 2015, 126, 4993-4993.	0.6	0
219	Natural History of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era. <i>Blood</i> , 2015, 126, 1456-1456.	0.6	0
220	Outcomes of DLBCL Patients Entering Surveillance (without maintenance) after Immunochemotherapy in a Large Observational Study. <i>Blood</i> , 2016, 128, 3036-3036.	0.6	0
221	Lenalidomide Plus R-CHOP (R2CHOP) in Patients with Follicular Lymphoma: Data from a Phase 1/2 Study. <i>Blood</i> , 2016, 128, 5322-5322.	0.6	0
222	Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 2935-2935.	0.6	0
223	Retinoic Acid Receptor Alpha Expression Drives Cell-Cycle Progression and Is Associated with Increased Sensitivity to Retinoids in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2016, 128, 1749-1749.	0.6	0
224	Lenalidomide in Combination with Standard R-CHOP Overcomes the Negative Prognostic Value of Peripheral Blood Absolute Lymphocyte/Monocyte Ratio at Diagnosis and during Treatment in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 4139-4139.	0.6	0
225	Non-Diffuse Large B-Cell Primary Central Nervous System Lymphoma. <i>Blood</i> , 2018, 132, 4208-4208.	0.6	0
226	Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder. <i>Blood</i> , 2018, 132, 2979-2979.	0.6	0
227	Development of a Hematology-Specific Fellowship Curriculum for Advanced Practice Providers Utilizing a Needs-Based Assessment. <i>Blood</i> , 2018, 132, 2236-2236.	0.6	0
228	Patterns of Care and Outcomes in Mantle Cell Lymphoma in the Modern Immunochemotherapy Era. <i>Blood</i> , 2018, 132, 4140-4140.	0.6	0
229	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. <i>Blood</i> , 2019, 134, 1532-1532.	0.6	0
230	Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R2-CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HRQoL) Analysis of the International Robust Study. <i>Blood</i> , 2019, 134, 3475-3475.	0.6	0
231	Characteristics of Patients with Relapsed/Refractory Burkitt Non-Hodgkin Lymphoma (NHL): Impact on the Feasibility of CAR-T Cell Therapy. <i>Blood</i> , 2019, 134, 5352-5352.	0.6	0
232	Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients. <i>Blood</i> , 2019, 134, 5215-5215.	0.6	0
233	Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 919-919.	0.6	0
234	Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse. <i>Blood</i> , 2019, 134, 923-923.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways. <i>Blood</i> , 2019, 134, 1480-1480.	0.6	0
236	Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era. <i>Blood</i> , 2019, 134, 422-422.	0.6	0
237	Mismatch-Repair Deficiency in Follicular Lymphoma Tumors Is Common and Associated with a Favorable Overall Survival. <i>Blood</i> , 2021, 138, 3523-3523.	0.6	0
238	Characteristics, Management and Outcomes of Patients with Intravascular Lymphoma: A Mayo Clinic Experience. <i>Blood</i> , 2021, 138, 1452-1452.	0.6	0
239	Impact of Diagnosis-to-Treatment Interval on Overall Survival in Patients with Mantle Cell Lymphoma: A National Cancer Database Analysis. <i>Blood</i> , 2021, 138, 3549-3549.	0.6	0
240	PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts. <i>Blood</i> , 2021, 138, 2508-2508.	0.6	0
241	Estimation of Long-Term Survival with Tafasitamab + Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 9-10.	0.6	0
242	Lenalidomide/RCHOP (R2CHOP) Produces High Response Rates and Overall Survival in New, Untreated Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma- Results from MC078E. <i>Blood</i> , 2020, 136, 47-48.	0.6	0
243	What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey Among Leading International Experts. <i>HemaSphere</i> , 2022, 6, e680.	1.2	0
244	67-Year-Old Woman With Diarrhea and Weight Loss. <i>Mayo Clinic Proceedings</i> , 2022, 97, 364-369.	1.4	0
245	Finding a consensus on timeâ€œevent endpoints definitions in marginal zone lymphoma: A Delphi method. <i>Hematological Oncology</i> , 2022, 40, 1086-1089.	0.8	0
246	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. <i>JCO Oncology Practice</i> , 2022, , OP2100789.	1.4	0
247	Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).. <i>Journal of Clinical Oncology</i> , 2022, 40, 7560-7560.	0.8	0
248	Phase 1 results of a phase 1/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3084-3084.	0.8	0
249	Pharmacokinetics (PK) and pharmacodynamics (PD) in First-MIND: A phase Ib, open-label, randomized study of tafasitamab (tafa) ± lenalidomide (LEN) in addition to R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2022, 40, e19553-e19553.	0.8	0